Our single-center institutional experience with anti-PD-1 in locally advanced or metastatic cSCC patients demonstrated its effectiveness and safety in the real-world setting, regardless of age or ECOG performance status. The gene discussed is PDCD1; the disease is skin squamous cell carcinoma.